Rocket Pharmaceuticals Bolsa (NASDAQ: RCKT)

Últimas noticias sobre Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa

ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

On Monday, June 2, U.S. markets closed higher as optimism over trade talks persisted despite Trump&#8217;s plan to double steel and aluminum tariffs. China called his accusations &#8220;groundless.&#8221; Steel stocks surged while automakers fell. Nvidia and Meta gained; Tesla slipped. Manufacturing contracted for a third month. Traders anticipate Fed rate cuts, with key jobs data due Friday.
According to economic data, U.S. manufacturing activity slipped in May, with ISM PMI falling to 48.5, which is below forecasts. Construction spending also dropped 0.4% in April after a 0.8% decline in March.
Most S&amp;P 500 sectors rose Monday, led by energy, communication services, and tech. Industrials, however, ended the day in the red.
The Dow closed higher by 0.08% at 42,305.48, the S&amp;P 500 gained 0.41% to 5,935.94, and the Nasdaq rose 0.67% to 19,242.61.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Tuesday, Japan&#8217;s Nikkei 225 closed 0.05% lower at 37,453.50, led by losses in the Paper &amp; Pulp, Transport, and Communication sectors.
Australia&#8217;s S&amp;P/ASX 200 rose 0.63%, ending the session at 8,466.70, led by gains in the Gold, Financials, and Consumer Staples sectors.
India&#8217;s Nifty 50 was down 0.67% at 24,549.45, and the Nifty 500 slid 0.52% to 22,713.90.
China&#8217;s Shanghai Composite was up 0.43% at 3,361.98, and Shanghai Shenzhen CSI 300 gained 0.31% to 3,852.01.
Hong Kong&#8217;s Hang Seng closed the session 1.53% higher at 23,512.49.
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was down 0.19%.
Germany&#8217;s DAX index gained 0.13%.
France&#8217;s CAC 40 fell 0.27%.
U.K.&#8217;s FTSE 100 index traded lower by 0.13%.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading higher by 0.24% at $62.68/bbl, and Brent was up 0.20% at $64.75/bbl.
Natural gas rose 0.08% to $3.697.
Gold traded lower by 0.41% to $3,383.00, Silver fell 0.75% to $34.432, and Copper was down 1.87% to $4.7677.
<h2 class="wp-block-heading">U.S. Futures at 05:45 AM ET</h2>
Dow Jones futures slid 0.38%, the S&amp;P 500 declined 0.39%, and the Nasdaq 100 was down 0.33%.
U.S. futures slipped Tuesday as investors weighed Trump&#8217;s tariff threats, trade uncertainty with China, economic data, and inflation risks
<h2 class="wp-block-heading">Forex at 05:45 AM ET</h2>
The U.S. dollar index gained 0.22% to 98.90, the USD/JPY rose 0.10% to 142.86, and the USD/AUD rose 0.61% to 1.5485.
The U.S. dollar edged up Tuesday but stayed near six-week lows as trade policy uncertainty and weak manufacturing data pressured the outlook.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mixed Slip, Dollar Index Ticks Higher - Global Markets Today While US Slept

PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) faces mounting challenges as its Temu platform struggles with significant user losses following major U.S. trade policy shifts that eliminated key cost advantages for Chinese e-commerce platforms.
What Happened: Daily U.S. users of Temu fell 58% in May, according to market intelligence firm Sensor Tower, reported Reuters. The decline followed the White House&#8217;s May 2 decision to end the &#8220;de minimis&#8221; provision, which previously allowed Chinese companies to ship packages valued under $800 to the U.S. tariff-free.
Temu responded by slashing U.S. advertising spending and shifting its fulfillment strategy. The platform now displays only products shipped from U.S.-based warehouses, with China-shipped items labeled &#8220;out of stock.&#8221; 
Previously, Temu operated by giving merchants responsibility for ordering and supplying products while managing logistics, pricing and marketing from China.
PDD&#8217;s <a href="https://www.benzinga.com/news/earnings/25/05/45616623/temu-parent-pdd-does-not-mention-tariffs-impact-blames-external-environment-and-ecosystem-investments-for-profit-plunge">first-quarter earnings reflected</a> these pressures. Revenue grew just 10% year-over-year to $13.18 billion, missing analyst estimates of $14.17 billion. Adjusted operating profit declined 36% to $2.52 billion, with margins falling from 32.9% to 19.1%.
See Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45740592/trump-sets-july-8-deadline-for-trade-deals-demands-best-offers-from-global-partners-by-wednesday-report">Trump Sets July 8 Deadline For Trade Deals, Demands Best Offers From Global Partners By Wednesday: Report</a>
Why It Matters: The tariff changes fundamentally disrupted Temu&#8217;s business model, which relied on direct shipments from Chinese suppliers to maintain ultra-low prices. 
The new regime imposes <a href="https://www.benzinga.com/government/regulations/25/05/45189952/amazon-rival-pdd-holdings-temu-halts-china-to-us-shipments-amid-trumps-145-tariffs-actively-recruiting-us-sellers">90% duties or $75 per item on Chinese imports</a>, scheduled to increase to $150 per item by June. While competitor Shein has managed to increase per-customer spending despite similar challenges, Temu has struggled to adapt.
Price Action: PDD stock closed at $96.44 on Monday, down 0.07%. In pre-market trading on Tuesday, the stock rose 0.62% to $97.04. Year to date, PDD shares are down 0.46%.
PDD's Temu platform competes with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). According to Benzinga Edge Stock Rankings, PDD has a stronger valuation than Amazon but lacks momentum. The stock also shows a negative price trend across short to long term. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here to see the full stock breakdown</a>.
<figure class="wp-block-image aligncenter size-full is-resized"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="878" height="632" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03060017/image-20.png" alt="" class="wp-image-936355" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03060017/image-20.png 878w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03060017/image-20-300x216.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03060017/image-20-768x553.png 768w" sizes="(max-width: 878px) 100vw, 878px" /></a></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740537/forget-dollars-willy-woo-says-bitcoin-will-be-priced-against-global-gdp-gold-used-to-be-that-money-btc-is-the-challenger">Forget Dollars: Willy Woo Says Bitcoin Will Be Priced Against Global GDP — &#8216;Gold Used To Be That Money, BTC Is The Challenger&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

AMZN

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Amazon's Chinese Rival Temu Loses 58% Of US Users As End Of Tariff Loophole Hits Business Model

Rocket Lab Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) announced on Monday that the company successfully launched <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45738007/rocket-lab-successfully-launches-10th-electron-mission-for-multi-launch-customer-blacksky" rel="noreferrer noopener">its 65th Electron rocket</a> to deploy Earth-imaging satellites for BlackSky Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>).
This mission for BlackSky marks the tenth launch the company has conducted for them since 2019.
The &#8216;Full Stream Ahead&#8217; mission successfully launched from Rocket Lab Launch Complex 1 in Mahia, New Zealand, at 11:57 AM NZST (23:57 UTC on June 2nd).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/space/25/05/45633311/rocket-lab-stock-surges-on-geost-acquisition-strengthening-companys-positioning-for-golden-dome" rel="noreferrer noopener">Rocket Lab Stock Surges On Geost Acquisition, Strengthening Company&#8217;s Positioning For Golden Dome</a>
This flight successfully deployed a Gen-3 satellite for BlackSky into a 470 km circular Earth orbit, further expanding the company&#8217;s low Earth orbit constellation.
Notably, the Gen-3 satellite was deployed using a Rocket Lab Motorized Lightband, a separation system consistently provided by Rocket Lab for all of BlackSky&#8217;s Electron launches so far.
This mission marks the second in a series of four Electron launches that BlackSky has booked for 2025 to deploy its Gen-3 satellites.
Rocket Lab previously deployed the first of BlackSky&#8217;s new missions, &#8216;Fasten Your Seatbelts,&#8217; <a target="_blank" href="https://www.benzinga.com/25/02/43807615/fasten-your-space-belts-rocket-lab-expands-blacksky-partnership-with-60th-electron-mission-launch" rel="noreferrer noopener">earlier in February 2025</a>.
This BlackSky mission is Electron&#8217;s seventh successful launch in 2025 and Rocket Lab&#8217;s 65th overall, bringing the total number of satellites deployed by Electron to 226.
Both Rocket Lab CEO Sir Peter Beck and BlackSky CEO Brian O&#8217;Toole commented positively, emphasizing the reliability, increasing cadence, and agile deployment of BlackSky&#8217;s constellation to meet customer demands.
Investors can gain exposure to the stock via&nbsp;ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) and Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>).
Price Action: RKLB shares are up 0.79% at $26.81 premarket at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june" target="_blank" rel="noreferrer noopener">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a></li>
</ul>
Photo by Emagnetic via Shutterstock

Tech

ARKX

BlackSky Technology Inc. Class A Common Stock

BKSY

RKLB

Rocket Lab Launches 10th Mission for BlackSky

HC Wainwright &amp; Co. analyst Kevin Dede maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy and raises the price target from $7 to $12.

Price Target

Analyst Ratings

APLD

HC Wainwright & Co. Maintains Buy on Applied Digital, Raises Price Target to $12

Dog-themed cryptocurrency Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) was trading higher early Tuesday morning, outgaining cryptocurrency heavyweights.
What happened: The Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based meme coin rallied over 15% to become the second-biggest cryptocurrency gainer in the last 24 hours. The trading volume popped 76% to $438 million, suggesting high liquidity and trader interest.
WIF outgained blue-chip meme coins such as Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>), which grew 2.37% and 3.58%, respectively, in the last 24 hours.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/05/45556899/from-amazon-to-warren-buffetts-berkshire-hathawaybitcoin-is-now-bigger-than-these-wall-street-titans">From Warren Buffett&#8217;s Berkshire Hathaway To Jeff Bezos&#8217; Amazon — Bitcoin Is Now Outshining These Wall Street Titans</a>
The rally got the derivatives traders excited as well, as WIF's Open Interest soared 17% in the last 24 hours to $352.92 million, <a href="https://www.coinglass.com/BitcoinOpenInterest">according </a>to Coinglass.
Over 65% of top trader accounts on Binance were long on WIF, suggesting expectations of further upside.
Furthermore, the Bull Bear Power indicator, which measures the strength of buyers and sellers, flashed a "Buy" signal for WIF, <a href="https://in.tradingview.com/symbols/WIFUSD/technicals/">according </a>to TradingView. On the other hand, the Moving Average Convergence Divergence, which compares two exponential moving averages of price, painted a bearish outlook with a "Sell" signal.
Dogwifhat, a meme coin inspired by Dogecoin, depicts a Shiba Inu dog wearing a pink knitted hat. Launched in the fall of 2023, the feline coin exploded to a peak of $4.85 within the next four months, but has since retraced sharply. 
Price Action:&nbsp; At the time of writing, WIF was exchanging hands at $0.9830, up 15.96% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;Year-to-date, it has jumped over 76% in value
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45611404/anthony-scaramucci-remains-firm-on-bitcoin-as-the-best-investment-idea-even-as-the-largest-crypto-hovers-around-109000">Anthony Scaramucci Remains Firm On Bitcoin As The Best Investment Idea Even As The Largest Crypto Hovers Around $109,000</a></li>
</ul>
Image Via Shutterstock

$DOGE

$SHIB

$SOL

$WIF

Dogwifhat Is Outperforming Dogecoin, Shiba Inu Tuesday Morning: What's Going On?

Former President Barack Obama has opposed Republican efforts to scale back major provisions of the Affordable Care Act (ACA) in a recent social media post, urging voters to call their Senators to voice their resistance. &nbsp;
What Happened: In a post on X, Obama wrote, "Here's something everybody should be paying attention to: Congressional Republicans are trying to weaken the Affordable Care Act and put millions of people at risk of losing their health care.
Call your Senators and tell them we can&#8217;t let that happen." He also attached a Washington Post article explaining how President Donald Trump's "big, beautiful bill" is making way for reduced health insurance coverage for millions in the United States.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Here&#39;s something everybody should be paying attention to: Congressional Republicans are trying to weaken the Affordable Care Act and put millions of people at risk of losing their health care. Call your Senators and tell them we can&#39;t let that happen. <a href="https://t.co/jTKreuCNWZ">https://t.co/jTKreuCNWZ</a>
&mdash; Barack Obama (@BarackObama) <a href="https://twitter.com/BarackObama/status/1929583840630075458?ref_src=twsrc%5Etfw">June 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/politics/25/06/45740331/trumps-man-to-man-diplomacy-wont-work-with-xi-jinping-warns-former-white-house-chief-of-staff-as-tariff-deadlock-continues">Trump&#8217;s &#8216;Man-To-Man&#8217; Diplomacy Won&#8217;t Work With Xi Jinping, Warns Former White House Chief Of Staff As Tariff Deadlock Continues</a>
Why It Matters: The GOP Bill, which <a href="https://www.benzinga.com/25/05/45558613/house-advances-trumps-sweeping-one-big-beautiful-bill-after-key-medicaid-tax-and-border-security-changes">made its way through Congress</a> and is now being debated in the Senate, aims to <a href="https://www.benzinga.com/general/health-care/25/05/45344596/house-republicans-push-880-billion-medicaid-cuts-to-renew-trump-tax-breaks-democrat-warns-millions-will-lose-their-health-care">reduce federal health spending</a> by introducing changes to Medicaid and ACA insurance marketplaces.
These revisions could reduce enrolment in public health programs by more than 10 million people over the next decade. The changes wouldn't dismantle the ACA outright but would restrict eligibility, impose more frequent verification checks, shorten enrolment windows, and delay regulatory updates intended to simplify access.
The plan would also add work requirements for certain Medicaid enrolees and limit state mechanisms that increase federal matching funds. "It is very much like a backdoor repeal and replace," said Matt Salo, former executive director of the National Association of Medicaid Directors. The Congressional Budget Office projects that 7.6 million fewer people would be on Medicaid and 3.1 million fewer on ACA plans if the legislation is enacted.
Meanwhile, Office of Management and Budget Director&nbsp;Russell Vought&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/45717492/medicaid-cut-concerns-are-totally-ridiculous-says-trumps-budget-chief-russell-vought-quips-i-love-e" target="_blank" rel="noreferrer noopener">dismissed fears about Medicaid cuts</a>&nbsp;as &#8220;ridiculous,&#8221; and Speaker&nbsp;Mike Johnson&nbsp;(R-La.) argued that those who lose Medicaid&nbsp;<a href="https://benzinga.com/node/45716936" target="_blank" rel="noreferrer noopener">will do so by personal choice</a>.
Dr.&nbsp;Mehmet Oz, leading the Centers for Medicare and Medicaid Services (CMS), said the proposed eligibility requirements are not about withdrawing care but about making sure the <a href="https://www.benzinga.com/news/health-care/25/06/45719002/im-trying-to-save-medicaid-says-trump-appointed-cms-chief-dr-oz-as-cbo-estimates-7-6-million-could-lose-coverage-under-gops-big-beautiful-bill/">program survives long-term</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45718265/medicaid-cuts-backlash-grows-as-sen-joni-ernst-tells-voters-well-we-all-are-going-to-die-mocks-critics-from-a-cemetery">Medicaid Cuts Backlash Grows As Sen. Joni Ernst Tells Voters &#8216;Well, We All Are Going To Die,&#8217; Mocks Critics From A Cemetery</a></li>
</ul>
Photo courtesy: Gregory Reed / Shutterstock.com

Health Care

Politics

General

Barack Obama Accuses Republicans Of 'Trying To Weaken' Obamacare, Urges Voters To Call Their Senators As 'Millions Of People' Risk Losing Healthcare

Needham analyst John Todaro maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy and raises the price target from $10 to $12.

Needham Maintains Buy on Applied Digital, Raises Price Target to $12

Economist Peter Schiff has publicly criticized &#8220;The Big Short&#8221; fame investor Steve Eisman for <a href="https://www.benzinga.com/markets/equities/25/04/44830819/big-short-fame-steve-eisman-says-nvidias-best-days-are-not-behind-it-but-trump-is-the-wild-card-in-current-market">dismissing both gold investments and U.S. national debt concerns</a> during a recent media interaction. The exchange highlights growing tensions among financial experts over monetary policy and fiscal sustainability.
What Happened: Schiff wrote on X that Eisman&#8217;s stance reveals &#8220;incredible irony.&#8221; During the CNBC <a href="https://www.youtube.com/watch?v=qXR69STpehE">interview</a>, Eisman stated he&#8217;s &#8220;not a gold guy&#8221; and doesn&#8217;t monitor gold markets closely. He also expressed confidence in U.S. Treasuries, arguing he&#8217;s not worried about the $36.22 trillion national debt &#8220;so long as the world doesn&#8217;t have an alternative to Treasuries.&#8221;
The criticism comes as gold trades near $2,360 per ounce after pulling back from recent highs, while Treasury yields remain elevated with the 10-year note at 4.45% and 20-year bonds yielding 4.95%. Recent Moody&#8217;s credit rating concerns have pushed 30-year Treasury yields to near 5%, <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45500872/30-year-treasury-yields-hit-5-what-that-means-for-stocks">levels not seen since October 2023</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Big Short investor Steve Eisman just told <a href="https://twitter.com/CNBC?ref_src=twsrc%5Etfw">@CNBC</a> he&#39;s not a gold guy and doesn&#39;t watch or care about gold. He then said he&#39;s not worried about the U.S. national debt so long as the world doesn&#39;t have an alternative to Treasuries. The irony of those two statements is incredible.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1929651223235596479?ref_src=twsrc%5Etfw">June 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/politics/25/06/45740331/trumps-man-to-man-diplomacy-wont-work-with-xi-jinping-warns-former-white-house-chief-of-staff-as-tariff-deadlock-continues">Trump&#8217;s &#8216;Man-To-Man&#8217; Diplomacy Won&#8217;t Work With Xi Jinping, Warns Former White House Chief Of Staff As Tariff Deadlock Continues</a>
Why It Matters: Eisman, former senior portfolio manager at Neuberger Berman Group Inc. and current host of &#8220;The Real Eisman Playbook&#8221; podcast, gained fame for profiting from the 2008 subprime mortgage crisis. 
During his interview, he expressed caution about current markets, citing tariff uncertainties as his primary concern while maintaining positions in mega-cap technology stocks.
When challenged on social media about investment performance comparisons, one user noted that Eisman&#8217;s subprime short generated over $1 billion compared to potential gold returns of $40-80 million during the same period. However, Schiff countered that current conditions present different opportunities, calling U.S. dollars and Treasuries &#8220;the next big short.&#8221;
Schiff defended his macro analysis expertise, noting he also participated in subprime shorting but maintains &#8220;a much better understanding of global macro&#8221; dynamics. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">That was then. This is now. He is missing the next big short. The U.S. dollar and treasuries.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1929685857742868691?ref_src=twsrc%5Etfw">June 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/futures/25/06/45740778/us-stocks-likely-to-open-lower-expert-highlights-technical-analysis-showing-sp-500s-recovery-is-real-and-not-a-bull-trap-or-bear-market-rally">US Stocks Likely To Open Lower: Expert Highlights Technical Analysis Showing S&amp;P 500&#8217;s &#8216;Recovery Is Real&#8217; And Not A &#8216;Bull Trap&#8217; Or &#8216;Bear Market Rally&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Bonds

Peter Schiff Calls Out 'The Big Short' Investor Steve Eisman For Dismissing Gold And US Debt Concerns: 'The Irony Is Incredible'

HC Wainwright &amp; Co. analyst Scott Buck reiterates Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) with a Buy and maintains $3 price target.

Reiteration

YTRA

HC Wainwright & Co. Reiterates Buy on Yatra Online, Maintains $3 Price Target

UUUU

Energy Fuels Reports Record Uranium Production and Expands Resource Base With New Bullfrog Technical Report And Accelerated U.S. Permitting

National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.20 by 30 percent. This is a 6.67 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $303.10 million which missed the analyst consensus estimate of $341.73 million by 11.30 percent. This is a 2.11 percent increase over sales of $296.85 million the same period last year.

Earnings

Earnings Misses

NESR

National Energy Services Q1 Adj. EPS $0.14 Misses $0.20 Estimate, Sales $303.10M Miss $341.73M Estimate

WTER

The Alkaline Water Company Expands National Footprint With Strategic Distribution Agreement Covering 16,000 Locations Across 32 States

Alto Neuroscience, Inc. ("Alto") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally defined as a failure on two or more antidepressants.
The most advanced program, ALTO-207 (formerly known as CTC-501), is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for the treatment of Parkinson's disease with demonstrated antidepressant effect, and ondansetron, an antiemetic, selective 5-HT3 receptor antagonist. As a fixed-dose combination, ALTO-207 is designed to enable rapid titration and higher dosing by mitigating the dose-limiting adverse events typically experienced with pramipexole. ALTO-207 is being developed to address the significant unmet need for patients with TRD.
"The expansion of our pipeline aligns with Alto's mission to drive innovation in psychiatry through novel therapeutic solutions," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "With proprietary insights on dopamine biomarkers in depression that enable targeted neuropsychiatric drug development, we are uniquely positioned to advance ALTO-207, a differentiated, late-stage product candidate with robust clinical effects to date, which are supported with historical pramipexole data. The fixed-dose combination of pramipexole and ondansetron offers a novel treatment strategy designed to optimize for a rapid treatment effect with faster titration, and balance safety and tolerability at high doses. We believe the convenience of a single prescribable agent will also improve compliance and support clinician and patient adoption. Leveraging our targeted biomarker approach to stratify for TRD patients most likely to respond to treatment, we look forward to building on the positive Phase 2a results and initiating a Phase 2b trial, with a potentially pivotal design, by mid-2026."
Dr. Etkin continued, "The strategic transaction with Chase Therapeutics allows us to add a major late-stage clinical readout to our pipeline without changing our current cash runway guidance into 2028. Broadly, we believe this opportunity underscores the robust value of our precision platform and bolsters our prospects for long-term growth through driving innovation in psychiatry."
Thomas Chase, M.D., President and Chief Executive Officer of Chase Therapeutics Corporation, added, "Supported by the robust clinical effects in our completed Phase 2a study, we believe CTC-501, has the potential to address the critical need for more effective, mechanistically distinct interventions for patients with TRD. Given Alto's expertise in dopamine-related products in depression, we believe they are an ideal partner to maximize the therapeutic potential of our portfolio in depression and Parkinson's disease. We look forward to seeing Alto continue this exciting momentum as they work toward realizing our shared vision for patients."
Michael Browning, DPhil, MB.BS, MRCP, MRCPsych, Professor of Computational Psychiatry, University of Oxford, commented, "I am highly encouraged by the recently completed PAX-D study of pramipexole, which suggests a greater and more durable effect than other available TRD treatments. However, pramipexole is not well tolerated and when it is, it requires slow titration due to dose-limiting AEs. The clinical utility of pramipexole would be greatly enhanced by improving the dose-limiting tolerability profile. Emerging data suggests that ALTO-207 could address these challenges, and be well positioned to treat this large and underserved patient population."
Alto acquired CTC-501 (now ALTO-207), in development for depression, and CTC-413 (now ALTO-208), in development for Parkinson's disease. Both product candidates are novel patent-protected dopamine agonists.
About the Completed Phase 2a Trial for CTC-501
Chase Therapeutics completed a randomized, placebo-controlled Phase 2a clinical trial evaluating CTC-501 in 32 patients with depression. The study consisted of two periods, a dose titration period in which patients were dosed with increasing dose levels of CTC-501 or placebo at increments of 1 mg/day (or matching placebo) until the maximum allowed dose (or first intolerable dose) was reached. Patients were then maintained for an eight-week treatment period at either the maximum allowed dose or their maximum tolerated dose (1 mg/day lower than their first intolerable dose in the titration period). The primary endpoint in the study was defined as overall tolerability and achievement of higher dose levels of pramipexole when combined with ondansetron. Clinical efficacy was evaluated as a secondary exploratory endpoint in the study.
The primary endpoint was achieved in the study. Patients randomized to receive CTC-501 reached a mean dose of 4.1mg per day with 67% of patients achieving the highest allowable dose of 5mg/day. CTC-501 was generally well tolerated in the maintenance period of the study.
The clinical efficacy measures were evaluated as secondary endpoints and across measures CTC-501 demonstrated large, clinically meaningful, effects. CTC-501 demonstrated statistically significant and clinically meaningful improvements from baseline compared to placebo on depression symptoms as measured by the Montgomery Åsberg Depression Rating Scalef, or MADRS (LSM Δ vs. placebo at Week 8 = -8.2, p=0.025, Cohen's d=1.1). CTC-501 also demonstrated a significantly greater improvement compared to placebo on the Clinician Global Impression Scale of Severity, or CGI-S (LSM Δ vs. placebo at Week 8 = -0.76, p=0.04, Cohen's d=1.0).
About the Completed Phase 2a Trial for CTC-413
ALTO-208 is a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist. ALTO-208 is being developed for patients with Parkinson's disease (PD).
Chase Therapeutics completed a blinded Phase 2a clinical trial evaluating CTC-413 (pramipexole co-administered with aprepitant) in 13 patients with PD. The study consisted of two periods. Patients in the treatment group were initially titrated to the maximum allowed dose of standard pramipexole extended release (4.5 mg/day). Patients were then switched to CTC-413 until the maximum allowed dose of 9mg/day (or first intolerable dose) was reached. Following three months of maintenance, patients returned to their pre-study regimen for final assessment.
The mean tolerated dose of CTC-413 significantly exceeded pramipexole (p&lt;0.001). Six subjects (67%) tolerated CTC-413 at the maximum dose of 9.0mg/day and all but one remained on that dose throughout the final three-month treatment period. CTC-413 demonstrated favorable safety and tolerability with no unexpected, serious or persistent issues.
About the Transaction
Under the terms of the asset purchase agreement, Alto paid Chase Therapeutics an upfront payment of $1.75 million, and Chase Therapeutics will be eligible for up to an aggregate of $71.5 million in future milestone payments related to prespecified development and commercial milestones. $41 million of the potential future milestone payments are tied to commercial success of the product candidates.
Alto's financial guidance remains unchanged. The Company expects its current cash balance to support planned operations into 2028, now through five clinical trial readouts across its pipeline programs.

ANRO

Alto Buys Depression and Parkinson's Drug Portfolio for $1.75M Upfront, With $71.5M in Future Milestones

Guidance

Donaldson Revised Guidance For FY25 Sales To Be Up 1% To 3% (From Flat To Up 4% Earlier)

Donaldson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) raises FY2025 Adj EPS guidance from $3.60-$3.68 to $3.64-$3.70 vs $3.60 analyst estimate..

Donaldson Raises FY2025 Adj EPS Guidance from $3.60-$3.68 to $3.64-$3.70 vs $3.60 Est

Cango Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) ("Cango" or the "Company") today announced its production update for crypto mining business in May 2025.
&nbsp;
Bitcoin Mining Update for May 2025
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Metrics</td>
<td colspan="1" rowspan="1">May 2025 1</td>
<td colspan="1" rowspan="1">Apr 2025 1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Number of Bitcoins produced</td>
<td colspan="1" rowspan="1">484.5</td>
<td colspan="1" rowspan="1">470.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average number of Bitcoins produced per day</td>
<td colspan="1" rowspan="1">15.63</td>
<td colspan="1" rowspan="1">15.67</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total number of Bitcoins held 2</td>
<td colspan="1" rowspan="1">3,429.3</td>
<td colspan="1" rowspan="1">2,944.8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total number of Bitcoins sold 2</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Deployed hashrate 2</td>
<td colspan="1" rowspan="1">32 EH/s</td>
<td colspan="1" rowspan="1">32 EH/s</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average operating hashrate 3</td>
<td colspan="1" rowspan="1">29.86 EH/s</td>
<td colspan="1" rowspan="1">29.94 EH/s</td>
</tr>
</tbody>
</table>
</figure>

CANG

Cango Mines 484.5 Bitcoins in May, Boosts Holdings to Over 3,400 Without Selling Any

Future Fund LLC's managing director, Gary Black, thinks Elon Musk's Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) needs a pickup truck with a more conventional design as Cybertruck deliveries plunge.
What Happened: "With Cybertruck FY'25 deliveries currently tracking at just ~20,000, it's time for $TSLA to consider a cheaper (~$40-$50K), more conventional-looking Tesla pickup to capitalize on the global pickup truck opportunity," the investor said in a post on X on Tuesday.
He also outlined how, unlike a scaled-down Model Y, the new truck with some design cues from the new Model Y, "would likely have minimal cannibalization on existing TSLA models," Black said.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/45739688/ford-recalls-over-29500-f-150-lightning-pickup-trucks-over-suspension-defect">Ford Recalls Over 29,500 F-150 Lightning Pickup Trucks Over Suspension Defect</a>
The investor finally shared that if Musk's EV giant can capture at least 2% of the global pickup truck sector, it "could translate to incremental earnings of $800M, worth potentially $80B ($25/share) at a 100x P/E," Black noted.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">With Cybertruck FY'25 deliveries currently tracking at just ~20,000, it's time for <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> to consider a cheaper (~$40-$50K), more conventional-looking Tesla pickup to capitalize on the global pickup truck opportunity (6-7% of industry volume ~6M annual TAM). Unlike a scaled-down…
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1929793773766164808?ref_src=twsrc%5Etfw">June 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Black's comments come as the Cybertruck is proving to be a difficult product to sell for Musk and Tesla. The company reportedly has over <a href="https://www.benzinga.com/markets/25/05/45216453/tesla-has-over-10000-units-of-unsold-cybertrucks-in-its-us-inventory-amid-poor-sales-report">10,000 units of unsold Cybertrucks </a>in its U.S. inventory, demonstrating the product's lack of appeal among traditional pickup buyers.
The EV giant even revamped the <a href="https://www.benzinga.com/news/25/04/44967503/cybertruck-gets-a-down-to-earth-redesign-as-tesla-shifts-to-traditional-pickup-marketing-amid-poor-s">Cybertruck's marketing strategy</a> to position the vehicle as a utilitarian workhorse with visuals of the Cybertruck hauling a trailer, tackling a dirt road, as well as hauling construction material.
Meanwhile, the company has also started <a href="https://www.benzinga.com/25/05/45487522/tesla-is-accepting-trade-ins-for-2024-cybertruck-amid-plummeting-sales-figures-report">accepting trade-ins </a>for the Cybertruck just over a year after the product launched. Tesla reportedly offered $65,400 for an All-wheel-drive 2024 Cybertruck with 6,211 miles to a Cybertruck owner as a trade-in.
Elsewhere, Black recently shared that his firm offloaded its remaining stake in Tesla, a move that was in line with <a href="https://www.benzinga.com/markets/equities/25/06/45737979/cathie-wood-sells-tesla-stock-as-chinese-rivals-gain-ground-ark-dumps-palantir-amid-privacy-concerns">other expert analysts </a>like Cathie Wood and even insiders like Musk's brother, Kimbal Musk.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="184" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-1024x184.jpg" alt="" class="wp-image-936305" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-1024x184.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-300x54.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-768x138.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-1536x277.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1.jpg 1649w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
TSLA scores well on Momentum, Growth, and Quality metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45740083/elon-musks-tesla-files-new-autonomous-taxi-trademark-application-ahead-of-robotaxi-launch-in-june">Elon Musk&#8217;s Tesla Files New Autonomous Taxi Trademark Application Ahead Of Robotaxi Launch In June</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

TSLA

Tesla Needs To Consider A 'More Conventional-Looking' Pickup Truck Says Gary Black Amid Cybertruck Sales Slump

SMNEY

Eaton And Siemens Energy Partner To Deliver Modular, Grid-Independent Power Solutions For Rapid Data Center Deployment

Donaldson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) reported quarterly earnings of $0.99 per share which met the analyst consensus estimate. This is a 7.61 percent increase over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $940.10 million which missed the analyst consensus estimate of $943.02 million by 0.31 percent. This is a 1.31 percent increase over sales of $927.90 million the same period last year.

Donaldson Q3 Adj. EPS $0.99, Inline, Sales $940.10M Miss $943.02M Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy and maintains $80 price target.

PTGX

HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $80 Price Target

Press Releases

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Comments

Rocket Pharmaceuticals

Noticias

Últimas noticias sobre Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL